GLP-1 News

FDA Moving to Ban Compounded Semaglutide and Tirzepatide

4 min read · Published 04-30-2026 · Sources cited to FDA / NIH / clinical trials

The U.S. Food and Drug Administration is proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a move that could effectively end large-scale compounding of GLP-1 medications. The agency says it has found no clinical need for outsourcing facilities to produce these drugs from bulk substances — a decision that directly affects the many patients who currently rely on compounded versions of Ozempic, Wegovy, Mounjaro, or Zepbound.

What the 503B Bulks List Actually Means

Under U.S. pharmaceutical law, 503B outsourcing facilities are large, FDA-registered compounding operations that can produce drugs in bulk quantities for distribution to healthcare providers — without individual patient-specific prescriptions. To legally compound a drug from bulk substances, that drug must appear on the FDA's 503B bulks list.

Semaglutide and tirzepatide were permitted on that list largely because of documented shortages of brand-name GLP-1 products. With the FDA now proposing their removal — alongside liraglutide — the agency is effectively signaling that it no longer considers a clinical justification sufficient to allow this large-scale compounding to continue.

Why This Matters for GLP-1 Patients

Compounded GLP-1 medications surged in popularity as shortages of Ozempic, Wegovy, Mounjaro, and Zepbound made brand-name drugs hard to obtain. Compounded versions were also frequently cheaper, attracting patients who faced high out-of-pocket costs for the branded products.

If this proposal is finalized, outsourcing facilities would no longer be permitted to produce and sell bulk-compounded semaglutide, tirzepatide, or liraglutide. Patients currently using these compounded medications could face disruption to their supply and may need to transition to FDA-approved brand-name alternatives.

Key takeaway: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for outsourcing facilities to compound them. If finalized, this would effectively prohibit large-scale compounding of these GLP-1 drugs — impacting patients who depend on lower-cost compounded versions.

What Happens Next

This is currently a proposal, not a final rule. FDA proposals of this type typically go through a public comment and review period before any final determination is made. Compounding pharmacies, patient advocates, and healthcare providers will likely weigh in during that process.

Patients and prescribers should monitor FDA announcements closely, as a finalized exclusion would set a firm deadline for outsourcing facilities to stop compounding these substances.

Frequently Asked Questions

Not yet. The FDA has issued a proposal to exclude these drugs from the 503B bulks list, but it has not been finalized. Until a final rule is issued, current compounding activities may continue, though patients should prepare for potential changes.
The FDA's proposal specifically names semaglutide (the active ingredient in Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), and liraglutide (Victoza and Saxenda).
The FDA stated it found no clinical need for outsourcing facilities to compound these drugs from bulk substances. This is the agency's stated basis for proposing their removal from the 503B bulks list.
Don't stop your medication without talking to your prescriber first. Use this time to have a conversation about your options, including whether FDA-approved brand-name alternatives are accessible and affordable for you if the proposal becomes final.
The FDA's proposal specifically targets 503B outsourcing facilities, which are large-scale compounders. The rules governing smaller, patient-specific 503A compounding pharmacies operate under a separate framework. Consult your pharmacist or prescriber about how any final rule might affect your specific situation.

If you currently use a compounded GLP-1 medication or are considering switching, speak with your prescriber before making any changes. They can help you understand how this regulatory development may affect your treatment plan and guide you toward the safest, most appropriate options for your individual needs.

Sources
  • FDA RSS feed, 'FDA Moving to Ban Compounded Semaglutide and Tirzepatide', date not specified

Keep Reading

Do GLP-1 Medications Reduce Alzheimer's Risk? What New Studies ShowResearch & News · 6 min readNext-Generation GLP-1 Drugs in the Pipeline: What Is Coming After TirzepatideResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.